<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-147872</identifier>
<setSpec>0212-6982</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Metastatic gastroenteropancreatic neuroendocrine tumours: 111in-pentetreotide and PET-FDG imaging</dc:title>
<dc:description xml:lang="en">We present a patient with previous history of neuroendocrine tumour in the head of the pancreas, well differentiated and treated surgically. Two years later, there was suspicion of relapse. An endoscopy, CT scan and 111In-pentetreotide scintigraphy were performed. The 4 hour image showed two uptake lesions in the liver and the peripancreatic region. However, these focal uptakes had disappeared in the 24 hour image. In view of this result, a PET-FDG scan was carried out, showing two hypermetabolic lesions. The biodistribution of 111In-pentetreotide may be influenced by various parameters, including the time of scanning, and may show neuroendocrine tumours without somatostatin receptors in relapses. PET-FDG is an interesting tool to help characterise these cases (AU)</dc:description>
<dc:creator>Lancha Hernández, C</dc:creator>
<dc:creator>Serra Arbeloa, P</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Presentamos el caso de una paciente con el antecedente de un tumor neuroendocrino de la cabeza del páncreas, bien diferenciado, que es tratada mediante cirugía. Dos años después, ante la sospecha clínica de recidiva se le practica una endoscopia, una TAC y un rastreo con 111In-pentetreótido. En la imagen de las 4 horas se observaron lesiones con receptores de somatostatina en el hígado y en la región peripancreática. No obstante, esta captación desaparece a las 24 horas. Ante este hallazgo se realiza una PET-FDG mostrando focos de elevado metabolismo en ambas lesiones. La biodistribución del 111In-pentetreótido puede ser variable en el tiempo, y ser captada por tumores sin expresión previa de receptores de somatostatina en las recidivas. La PET-FDG puede ayudar en estos casos (AU)</dc:description>
<dc:source>Rev Esp Med Nucl;27(3): 199-201, mayo 2008. ilus</dc:source>
<dc:identifier>ibc-147872</dc:identifier>
<dc:title xml:lang="es">Tumor neuroendocrino del sistema gastroenteropancreático metastásico: imagen con 111In-pentetreótido y PET-FDG</dc:title>
<dc:subject>^d23482</dc:subject>
<dc:subject>^d8287^s22064</dc:subject>
<dc:subject>^d31255^s22064</dc:subject>
<dc:subject>^d22676^s22003</dc:subject>
<dc:subject>^d22923^s22079</dc:subject>
<dc:subject>^d30544^s22002</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d38793</dc:subject>
<dc:subject>^d24501^s22027</dc:subject>
<dc:subject>^d8384^s22008</dc:subject>
<dc:subject>^d31255^s22008</dc:subject>
<dc:subject>^d33478^s22079</dc:subject>
<dc:subject>^d31255^s22009</dc:subject>
<dc:subject>^d10378^s29165</dc:subject>
<dc:subject>^d10378^s22009</dc:subject>
<dc:subject>^d22676^s22079</dc:subject>
<dc:subject>^d10378^s22008</dc:subject>
<dc:subject>^d5289</dc:subject>
<dc:subject>^d29913</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d23311</dc:subject>
<dc:subject>^d31255^s29165</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d8287^s29165</dc:subject>
<dc:subject>^d9556^s22002</dc:subject>
<dc:subject>^d33090^s22079</dc:subject>
<dc:subject>^d8287^s22008</dc:subject>
<dc:type>article</dc:type>
<dc:date>200805</dc:date>
</metadata>
</record>
</ibecs-document>
